Recent studies indicate that individuals with SCD may exhibit abnormalities in AD biomarkers, such as reduced cerebrospinal fluid (CSF) Aβ42 levels and increased phosphorylated tau, suggesting a potential progression toward AD. Here, MAPT is linked to Alzheimer disease.